ArticleEcancermedicalscience2026
Clinical and laboratory characteristics and management in patients diagnosed with multiple myeloma: real-world cohort in a Peruvian referral clinic.
Article in Ecancermedicalscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM) is a malignant proliferation of clonal plasma cells causing bone lesions, renal impairment, anemia and hypercalcemia. Real-world data on the clinical characteristics, treatment patterns and outcomes of patients with MM in Latin America, particularly in Peru, remain scarce. This study aimed to describe the clinical and laboratory features, characteristics, treatment and 5-year survival of MM patients in a Peruvian referral clinic. Methods: We conducted a retrospective cohort study including adult patients diagnosed with MM (ICD-10 C90.0) between 2016 and 2020, identified from institutional clinical records. Demographic, clinical, laboratory and treatment data were collected. Overall survival was estimated using Kaplan-Meier. Results: Among transplant recipients, women predominated (52.2%), whereas men predominated in the total cohort (52.4%). The mean age was 55.5 years for transplant patients and 60.6 for all patients. Eastern Cooperative Oncology Group (ECOG) 1 was most common (52.2%) and stage III was frequent (48.9% transplant; 47.3% overall). Vertebral lesions were predominant (69.6% transplant; 65.5% overall). Bortezomib-lenalidomide-dexamethasone (VRd) was the main first-line regimen (69.6% and 68.3%, respectively). Five-year survival was 87.9% for transplant recipients and 64.8% overall. Conclusion: MM patients commonly presented with advanced stage, vertebral lesions, ECOG 1 and received VRd; transplant recipients achieved excellent survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.